Gilenya Assessment Report: 84 DEATHS!!!, by CCSVI in MS Toronto For those who may want to see what goes on during the development cycle of a new drug, please see the attached Gilenya Assessment Report PDF. The data and statement below speaks for itself. WaYnE Page 88 - 2.6.3. Serious adverse event/deaths/other significant events DeathsA total of 84 deaths were reported in the clinical development program including 12 patients in the MS and ongoing studies (cut off date: 30 September 2009) and - facebook prikbord

Chronische Cerebro-Spinale Veneuze Insufficiëntie

A- A+

Over CCSVI.nl | Zoeken | Contact | Forum

CCSVI.nl is onderdeel van de
Franz Schelling Website
meer informatie

Gilenya Assessment Report: 84 DEATHS!!!, by CCSVI in MS Toronto For those who may want to see what goes on during the development cycle of a new drug, please see the attached Gilenya Assessment Report PDF. The data and statement below speaks for itself. WaYnE Page 88 - 2.6.3. Serious adverse event/deaths/other significant events DeathsA total of 84 deaths were reported in the clinical development program including 12 patients in the MS and ongoing studies (cut off date: 30 September 2009) and

Monday, April 18, 2011 9:45 AM | Venöse Multiple Sklerose, CVI & SVI, CCSVI

Gilenya Assessment Report: 84 DEATHS!!!, by CCSVI in MS Toronto
For those who may want to see what goes on during the development cycle of a new drug, please see the attached Gilenya Assessment Report PDF. The data and statement below speaks for itself. WaYnE Page 88 - 2.6.3. Serious adverse event/deaths/other significant events DeathsA total of 84 deaths were reported in the clinical development program including 12 patients in the MS and ongoing studies (cut off date: 30 September 2009) and 72 in the renal transplantation completed studies. Page 90 - Ser...http://www.facebook.com/notes/ccsvi-in-ms-toronto/gilenya-assessment-report-84-deaths/10150213160684919